nivolumab,ipilimumab,cabozantinib
bms,exelixis
['triplet,(-triplete)', 'cosmic-313']
special attention to the poor imdc risk group in the cosmic-313 trial! it might be associated with the higher tx discontinuation in the triplet arm??? #esmo22 
Medical Oncologist/T?bbi Onkolog
#genitourinary and #gastrointestinal cancers 
#computational oncology
Tweets for scientific purposes. Not medical advice!